Discover six companies advancing promising treatments for pulmonary hypertension beyond vasodilators, changing the standards of care.

Discover five myopia companies racing to go beyond glasses, as myopia is set to affect half the world by 2050.

Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer, as Hansoh Pharma and Medilink bring momentum with ...

Learn when TIDE-based Sanger sequencing can replace NGS for measuring on-target gene editing efficiency in regulated ...

Discover Novo's pipeline in 2026, as it recently set out a new plan to reach $23 billion in risk-adjusted pipeline sales by ...

In June, AstraZeneca once again turned to the Chinese company CSPC Pharmaceuticals, with whom it initially entered into an exclusive license agreement in October 2024 for an early-stage cardiovascular ...

If you were to look back just a little over two years ago to the start of 2021, then putting money into a biotech company seemed like a pretty safe bet. After all, the COVID-19 pandemic had shined a ...